Molecular Pharmacology (USA) Ltd. engages in the development of pharmaceutical products. The company is headquartered in Leederville, Western Australia. The company went IPO on 2005-05-20. Ltd. (MPLA) is in the business of developing and commercializing an analgesic and anti-inflammatory molecule known as Tripeptofen. The Company’s over-the-counter anti-pain and anti-inflammatory products sold for the treatment of acute localized pain are based on non-steroidal anti-inflammatory drugs (NSAIDs). The licensed products include all products in all dosage forms, formulations, line extensions and package configurations using production method of metallo-polypeptide analgesic and anti-inflammatory activity as an active ingredient marketed by MPLA or its affiliates under the trade name Tripeptofen. The firm and Molecular Pharmacology Pty. Ltd. have no manufacturing facilities.
Follow-Up Questions
Who is the CEO of Molecular Pharmacology (USA) Ltd?
Jeffery Edwards is the President of Molecular Pharmacology (USA) Ltd, joining the firm since 2005.
What is the price performance of MLPH stock?
The current price of MLPH is $0.0007, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Molecular Pharmacology (USA) Ltd?
Molecular Pharmacology (USA) Ltd belongs to N/A industry and the sector is N/A
What is Molecular Pharmacology (USA) Ltd market cap?
Molecular Pharmacology (USA) Ltd's current market cap is $699.6K
